AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04411030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Form: capsule; Route of administration: oral
Study NCT04831255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triamcinolone acetonide extended-release injectable suspension
Description: ZILRETTA (triamcinolone acetonide extended-release injectable suspension) injection in the glenohumeral joint administered under ultrasound guidance.
Study NCT03996694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belbuca 300 µg
Description: Belbuca 300 µg buccal film
Study NCT03996694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belbuca 600 µg
Description: Belbuca 600 µg buccal film
Study NCT03996694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belbuca 900 µg
Description: Belbuca 900 µg buccal film
Study NCT03996694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone 30 mg
Description: Oxycodone 30 mg capsule
Study NCT03996694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone 60 mg
Description: Oxycodone 60 mg capsule
Study NCT03996694 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo buccal film and oral placebo
Study NCT03441373 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: XC8 20 mg
Description: once daily during 5 days.
Study NCT03441373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC8 20 mg
Description: once daily during 5 days.
Study NCT01330758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8931
Description: 40 mg AZD8931 roller compacted tablet formulation
Study NCT01179971 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil, gamma-linolenic acid
Description: 3 g/d DHA + EPA
Study NCT01179971 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Fish oil, gamma-linolenic acid
Description: 3 g/d DHA + EPA
Study NCT00095758 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antidepressant + Placebo
Description: Antidepressant Caps/Tablets Placebo Tablets, Oral, 2-20 mg Placebo, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
Study NCT00095758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antidepressant + Aripiprazole
Description: Antidepressant Caps/Tablets Aripiprazole Tablets, Oral, 2-20 mg Aripiprazole, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
Study NCT00184015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab and Bortezomib
Description: Bevacizumab 15 mg/kg on day 1 with Bortezomib 1.0 or 1.3 mg/m2 on days 1, 4, 8 and 11 every 21 days
Study NCT00184015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab and Bortezomib
Description: Bevacizumab 15 mg/kg on day 1 with Bortezomib 1.6 or 1.8 mg/m2 on days 1 and 8 every 21 days
Study NCT01356433 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: oral vitamin C
Description: cross-over study,2 arms Arm 1(50cases): is given oral vitamin C 200mg per day in the first 3 months, then stop oral VitC for the next 3 months.~Arm 2(50cases): is not given vitamin C in the first 3 months, then switch to receive oral VitC 200mg per day in the next 3 months.
Study NCT04033055 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inguinal hernia repair with CycloMesh™ soaked in ropivacaine hydrochloride 10mg/mL
Description: The surgical technique for the inguinal hernia repair is the surgeon's usual technique: open surgery (Lichtenstein technique).~CycloMesh™ device (soaked in ropivacaine hydrochloride 10mg/mL) is positioned once the surgery for the inguinal hernia repair has been performed.
Study NCT04033055 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inguinal hernia repair with CycloMesh™ soaked in saline solution NaCl 9°/°°
Description: The surgical technique for the inguinal hernia repair is the surgeon's usual technique: open surgery (Lichtenstein technique).~CycloMesh™ device (soaked in saline solution) is positioned once the surgery for the inguinal hernia repair has been performed.
Study NCT04585204 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Oral glucose tolerance test
Description: Oral glucose tolerance test
Study NCT02161835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: 30 minutes of home based pulse watch regulated cycle-ergometer exercise, three times a week at 75% of maximal oxygen consumption.
Study NCT04463342 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Non Coated Glass Ionomer
Description: KetacTM Universal AplicapTM Glass Ionomer Restorative saves time by eliminating the need for a coating-yet still delivers the compressive strength and surface hardness that are higher than several competitive glass ionomers which require one.
Study NCT04463342 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Glass Ionomer with Coat
Description: Conventional Glass Ionomer with Coat
Study NCT02402582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family-centered empowerment model
Description: FCEM and Control groups had similar inpatient care. Patients in the intervention group received care employing the FCEM in four stages. Stage 1: Awareness and cognition. During 3-5 group sessions they were evaluated for their insight into their perceived illness severity and perceived sensitivity, or the degree to which they felt threatened by their illness. Stage 2: Expectations. 3-5 sessions. Stage 3: Acceptance. Assessed using an educational participation method in group discussion. Stage 4: Formative summative evaluations. The formative evaluation encourages patients to internalize their locus of control by seeing his/her self-empowerment (increasing self-responsibility about their health). Summative evaluations were performed to evaluate the influence of the intervention on HRQoL dimensions, perceived stress and anxiety -- assessed at baseline and at 3 months post-intervention. Empowerment was measured at baseline and at 10 days post-intervention by deploying FCEM questionnaires.
Study NCT02402582 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: FCEM and Control groups had similar inpatient care. Upon discharge the Control group underwent routine care and follow-up.
Study NCT03158324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPB-111077
Description: Receive 600 mg of OPB-111077 on a 4 days-on, 3 days-off per week in 28-day cycles till disease progression or intolerable toxicity
Study NCT00350688 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Helical tomotherapy IMRT
Description: Helical tomotherapy IMRT
Study NCT04698603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Methoxy N,N Dimethyltryptamine
Description: GH001 administered via inhalation
Study NCT03441373 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: XC8 100 mg
Description: once daily during 5 days.
Study NCT03441373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC8 100 mg
Description: once daily during 5 days.
Study NCT01356433 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: oral vitamin C
Description: Arm 2(50cases): is not given vitamin C in the first 3 months, then switch to receive oral VitC 200mg per day in the next 3 months.
Study NCT02969928 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full-mouth ultrasonic debridement
Description: Full-mouth ultrasonic debridement will be performed in order to treat diseased sites
Study NCT02969928 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full-mouth ultrasonic debridement
Description: Full-mouth ultrasonic debridement will be performed in order to treat diseased sites
Study NCT02837029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02837029 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT02837029 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Yttrium Y 90 Glass Microspheres
Description: Given IA
Study NCT03078556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Single dose of DTG 50 mg tablet along with 3TC (EPIVIR) tablet will be given to randomized subjects in parts 1 and 2 with 240 mL of room temperature water. DTG will be a white, film coated, round tablet engraved with SV 572 on one side and 50 on the other side.
Study NCT03078556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Single dose 3TC (commercial name: EPIVIR) 300 mg tablet along with DTG tablet will be given to randomized subjects in parts 1 and 2 with 240 mL of room temperature water.\<br>3TC will be gray, diamond shaped tablet, engraved GX EJ7 on one side and plain on the other side.
Study NCT03078556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir + Lamivudine FDC Formulation 1
Description: Single dose of DTG 50 mg combined with 3TC 300 mg in a FDC formulation 1 tablet will be administered to randomized subjects in treatment periods 1 and 2 (under fasted state) of Part 1 and the first 16 subjects in treatment period 3 (under fed) of Part 1 with 240 mL of room temperature water. \&lt;br\&gt;FDC formulation 1 tablets will be oval, biconvex, white, film coated tablet engraved 'SV H7I' on one face.
Study NCT03078556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir + Lamivudine FDC Formulation 2
Description: Single dose of DTG 50 mg combined with 3TC 300 mg in a FDC formulation 2 tablet will be administered to randomized subjects in treatment periods 1 and 2 (under fasted state) and the first 16 subjects in treatment period 3 (under fed) of Part 2 with 240 mL of room temperature water. \&lt;br\&gt;FDC formulation 2 tablets will be oval, biconvex, white, film coated tablet engraved 'SV 13N' on one face.
Study NCT03441373 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: XC8 200 mg
Description: once daily during 5 days.
Study NCT03441373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC8 200 mg
Description: once daily during 5 days.
Study NCT01817426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Study NCT01817426 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02128724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: Buparlisib is a highly specific inhibitor of phosphatidylinositol 3-kinase (PI3K). Buparlisib is supplied as 10mg and 50mg hard gelatin capsules.
Study NCT02780492 — intervention group
Intervention type: OTHER
Intervention: Set of assessment tools
Study NCT04994756 — intervention group
Intervention type: PROCEDURE
Intervention: Stroke/Thrombectomy/Aneurysm-specific surgical procedures
Description: Participants are retrospectively and/or prospectively entered into registry based on disease indication and respective surgical procedure.
Study NCT03213288 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Delphinidin type anthocyanins
Description: Bilberry extract containing Delphinidin type anthocyanins
Study NCT03213288 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cyanidin type anthocyanins
Description: Black rice extract containing Cyanidin type anthocyanins
Study NCT03213288 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No anthocyanins
Study NCT01159015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KetoNaph
Description: Ophthalmic Solution administered BID for 6 weeks
Study NCT01159015 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle of KetoNaph ophthalmic solution administered bid for six weeks
Study NCT03956966 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQL block with saline
Description: drug: saline 21 ml 0.9% normal saline administered on each side as bilateral TQL blocks Drug: fentanyl With induction of general anaesthesia, fentanyl (1 microgram.kg) will be given. Intraoperatively, fentanyl boluses (0.5 microgram.kg) will be given in case of increase in intraoperative mean arterial blood pressure or heart rate of more than 20% of baseline for longer than 5 minutes.~Drug: Paracetamol Paracetamol infusion (15 mg.kg) will be given by intravenous infusion after induction of general anesthesia. Postoperatively, 1 g of paracetamol will be given by intravenous infusion to all cases every 8 hours.~Drug: Ketorolac analgesia In PACU Ketorolac 30 mg ampoule will be given by intravenous infusion to all cases Drug: Nalbuphine Nalbuphine boluses 0.1 mg. /kg will be given as rescue analgesia if VAS is more than3.~Device: ultrasound-guided nerve block Transmuscular quadratus lumborum block, ultrasound-guided
Study NCT03956966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TQL block with Bupivacaine
Description: Drug: saline~1mL 0.9% normal saline administered on each side as bilateral TQL blocks drug: Bupivacaine 20 ml Bupivacaine hydrochloride 0.25% administered on each side as bilateral TQL blocks Drug: fentanyl With induction of general anaesthesia, fentanyl (1 microgram.kg) will be given. Intraoperatively, fentanyl boluses (0.5 microgram.kg) will be given in case of increase in intraoperative mean arterial blood pressure or heart rate of more than 20% of baseline for longer than 5 minutes.~Drug: Paracetamol 15 mg.kg will be given by intravenous infusion after induction of general anesthesia. Postoperatively, 1 g of paracetamol will be given to all cases every 8 hours.~Drug: Ketorolac In PACU Ketorolac 30 mg ampoule will be given by intravenous infusion to all cases Drug: Nalbuphine Nalbuphine boluses 0.1 mg. /kg will be given as rescue analgesia if VAS is more than 3.~Device: ultrasound-guided nerve block Transmuscular quadratus lumborum block
Study NCT03956966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TQL block with Bupivacaine and dexamethasone
Description: Drug: dexamethasone~1 mL dexamethasone 4mg administered on each side as bilateral TQL blocks drug: Bupivacaine 20 ml Bupivacaine hydrochloride 0.25% administered on each side as bilateral TQL blocks Drug: fentanyl With induction of general anaesthesia, fentanyl (1 microgram.kg) will be given. Intraoperatively, fentanyl boluses (0.5 microgram.kg) will be given in case of increase in MBP or HR of more than 20% of baseline for longer than 5 minutes.~Drug: Paracetamol Paracetamol infusion (15 mg.kg) will be given by intravenous infusion after induction of general anesthesia. Postoperatively, 1 g of paracetamol will be given by intravenous infusion to all cases every 8 hours.~Drug: Ketorolac In PACU Ketorolac 30 mg ampoule will be given by intravenous infusion to all cases Drug: Nalbuphine Nalbuphine boluses 0.1 mg. /kg will be given as rescue analgesia if VAS is more than 3.~Device: ultrasound-guided nerve block Transmuscular quadratus lumborum block
Study NCT02639442 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClearRing™
Study NCT00933322 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: diet enriched with industrial trans fatty acids
Description: After run-in phase of 2 weeks with margarine without TFA, 4 weeks with margarine enriched with industrial trans fatty acids following. TFA-percentage of total energy consumption is 2% or 6% of total fat energy consumption.
Study NCT00933322 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: diet enriched with ruminant trans fatty acids
Description: After run-in phase of 2 weeks with margarine without TFA, 4 weeks with butter enriched with ruminant trans fatty acids following. TFA-percentage of total energy consumption is 2% or 6% of total fat energy consumption.
Study NCT00933322 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: diet without any trans fatty acids
Description: 6 weeks with margarine without any trans fatty acids.
Study NCT01974622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Visudyne
Description: Half fluence verteporfin
Study NCT02984917 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior transversalis fascia approach
Description: Patients will undergo inguinal hernia repair via the anterior transversalis fascia approach.
Study NCT02984917 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preperitoneal space approach
Description: Patients will undergo inguinal hernia repair via the preperitoneal space approach.
Study NCT00413036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: once daily oral capsule
Study NCT03539718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taurolidine heparin
Description: Taurolock-hep 500 at end of session
Study NCT03539718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin Sodium
Description: Heparin sodium 5000 at end of session
Study NCT00394706 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Impedance Threshold Device (ITD)
Description: Use of Impedance Threshold Device (ITD)
Study NCT00394706 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham ITD
Description: Sham ITD
Study NCT00394706 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Analyze early
Description: Upon EMS arrival at the scene of a non-traumatic cardiac arrest, an assessment of the cardiac rhythm is done to determine whether a defibrillatory shock is required.
Study NCT00394706 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Analyze later
Description: Upon EMS arrival at the scene of a non-traumatic cardiac arrest, three minutes of CPR is given prior to the assessment of the cardiac rhythm to determine whether a defibrillatory shock is required.
Study NCT04094857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBN-1
Description: Intravenous infusion
Study NCT01649934 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation Intention
Description: Implementation Intentions are a series of what/when/where statements that a participant will make to create automatic cues to complete a behaviorally advantageous action.
Study NCT01649934 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contact Clinic
Description: Participants will be asked to sign a form indicating their need to contact the recommended clinics to make their appointments.
Study NCT03316638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: W0101 - Cohort A1
Description: Administered once every 2 weeks
Study NCT03316638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: W0101 - Cohort A2
Description: Administered every 3 weeks
Study NCT03316638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: W0101 - Expansion Phase
Description: Administered according to the recommended dose for expansion
Study NCT01247961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone acetate
Description: 10 mg intravenous given as single administration with optional repeat dose after 36 hours.
Study NCT01247961 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study NCT03441386 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Exercise Session
Study NCT02473900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP1403
Description: Oseltamivir 75mg
Study NCT02473900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0919
Description: Oseltamivir phosphate 75mg
Study NCT01403155 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-3401 + EP
Description: All subjects will receive 0.9mg/mL of study vaccine (INO-3401 DNA plasmid vaccine)at Day 0 and Month 3.
Study NCT02707146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visit Planner
Description: The Visit Planner is an application hosted on an iPad that guides the patient in preparing for the primary care visit
Study NCT02707146 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control Pamphlet
Description: Patients in the attention control arm will receive an approved educational handout on health lifestyle
Study NCT02707146 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iPad
Study NCT02041845 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 45 Gy in 30 fractions
Description: 3D conformal thoracic radiotherapy at a total dose of 45 Gy in 30 fractions, 2 fractions per day, 5 days a week
Study NCT02969928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Administration of Clarithromycin 500mg bid for 7 days
Study NCT02969928 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Administration of Amoxicillin 500mg tid for 7 days.
Study NCT02969928 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Administration of Metronidazole 400mg tid for 7 days.